Astellas Pharma announced it is acquiring Ocata Therapeutics for $379M. Headquartered in Tokyo, Japan, Astellas is the second largest drug company in Japan, generating over $10 billion in drug sales last year, while Ocata is headquartered in Marlborough, Massachusetts. Astellas’ cash flow is essential, because the company has agreed to pay $8.50 a share for Ocata, a 79% premium over the stock price last Friday. [Read more…]
A New Era of Science & Medicine: 3D Bioprinting with Stem Cells
Without question, 3D printing is one of the most transformative technologies of the 21st century, impacting diverse fields that include medicine, science, technology, manufacturing, military defense, and more.
If you are like me, the technology of 3D printing been increasingly catching my attention and interest. As a stem cell market research firm, BioInformant is committed to introducing new market forces as they emerge.
In my opinion, 3D bioprinting is a market force that will transform the stem cell industry. [Read more…]
Recently, BioInformant released an article titled, “Do You Know the Top 5 iPS Cell Influencers (Right Now)?” In it, we named the five most important thought leaders that are driving therapeutic and commercial progress with induced pluripotent stem cells (iPS cells) right now in 2015. One of the important individuals that we highlighted was Dr. Robert Lanza, Chief Scientific Officer of Ocata Therapeutics.
In response to this article, Ocata Therapeutics released a press release announcing that “Dr. Robert Lanza, Chief Scientific Officer of Ocata Therapeutics has been awarded the honor of iPSC industry influencer by BioInformant, a leading research firm serving the stem cell sector.” [Read more…]
Hitachi, Ltd. and the Center for iPS Cell Research & Application (CiRA) at Kyoto University Agree to Collaborate
Important news was announced today within the induced pluripotent stem cell (iPS cell) industry in a press release distributed by Hitachi, Ltd. The press release announced that Hitachi, Ltd. and the Center for iPS Cell Research and Application at Kyoto University have reached an agreement to collaborate in building a “healthy volunteers’ iPS cell panel.” [Read more…]
Cellular Dynamics International Announces Launch of CIRM hPSC Repository and First 300 iPSC Lines
Cellular Dynamics International (CDI), a FUJIFILM company since March of 2015, announced news today that has reverberated throughout the stem cell community, suggesting hope and progress for the future of stem cell research.
As an indisputable leader in the the manufacture and production of iPS cell products, Cellular Dynamics was awarded a $16 million grant by the California Institute of Regenerative Medicine in March of 2013. In that landmark funding awarded, CIRM allocated $16 million for CDI to create 3 induced pluripotent stem cell (iPSC) lines from 3000 healthy and diseased donors. At the same time, CIRM awarded Coriell Institute approximately $10 million to structure and store the iPSC lines within a secure biobanking facility, of which CDI was to be a “primary subcontractor.” [Read more…]